Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month.


GlobeNewswire Inc | Aug 3, 2020 08:10AM EDT

August 03, 2020

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month.

Thursday, August 6, 2020 Event: William Blair Biotech Focus Conference 2020 Time: 12:00 pm ET*Fireside chat

Thursday, August 13, 2020 Event: Canaccord Genuity 40th Annual Growth Conference Time: 4:30 pm ET*Company overview and business update presentation

Live webcasts of these events will be available under the Investors and Media section of Ailerons website at https://investors.aileronrx.com/. A replay of the webcasts will be archived on Ailerons website for 30 days following the respective events.

About Aileron Therapeutics

At Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.

In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients quality of life and help them better tolerate chemotherapy, potentially allowing patients to complete their treatment without dose reductions or delays. Our long-term vision is to provide chemoprotection for patients with p53-mutated cancers, which represents approximately 50% of cancer patients, regardless of cancer type or chemotherapeutic drug. Visit us at aileronrx.com to learn more.

Investor Contacts:

Aileron TherapeuticsRichard Wanstall, SVP Chief Financial Officer617-995-0900rwanstall@aileronrx.com

Hans C. VitzthumLifeSci Advisors, LLC.617-430-7578hans@lifesciadvisors.com

Media Contact:Liz Melone617-256-6622lmelone@aileronrx.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC